Loading clinical trials...

RECRUITING

Artificial Intelligence in Assessing Gastric Intestinal Metaplasia Via the EGGIM Score

NCT07257796•Qilu Hospital of Shandong University

Summary

The endoscopic grading system (EGGIM) has been widely used to assess the extent of gastric intestinal metaplasia during endoscopy. Investigators developed an artificial intelligence (AI) system to automatically evaluate the extent of gastric intestinal metaplasia (GIM) and calculate the EGGIM scores in endoscopy examination. This study is a prospective, multi-center study aimed at exploring the performance and reliability of AI-EGGIM scoring. This is a prospective study designed to validate the AI-EGGIM system in a larger cohort. The study protocol was developed based on preliminary experience from a prior investigation (NCT05464108).

Detailed Description

Gastric intestinal metaplasia (GIM) is an important precancerous stage in the gastric carcinogenesis cascade. The endoscopic grading system (EGGIM) has been proposed as a practical method to evaluate the extent of GIM during endoscopy. Investigators developed an artificial intelligence (AI) system to automatically assess the extent of GIM and calculate EGGIM scores from endoscopic examinations. This study is a prospective, multi-center study aimed at evaluating the accuracy, performance, and reliability of AI-assisted EGGIM scoring.

Eligibility

Age

40 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•patients aged 40-75 years who undergo the IEE examination
•patients who voluntarily sign the informed consent form

Exclusion Criteria

•patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric disorders who cannot participate in gastroscopy
•patients with previous surgical procedures on the stomach

Locations (3)

Qilu Hospital of Shandong University

Jinan, Shandong, China

Shandong First Medical University First Affiliated Hospital

Jinan, Shandong, China

Shandong Second Provincial General Hospital

Jinan, Shandong, China

Key Dates

Start Date

November 1, 2025

Primary Completion Date

May 31, 2027

Completion Date

December 31, 2027

Last Updated

December 2, 2025

Enrollment

3,000

ESTIMATED participants

Conditions

Intestinal Metaplasia of Gastric MucosaArtificial IntelligenceEndoscopy

Interventions

The diagnostic performance of AI system and endoscopists

DIAGNOSTIC_TEST

Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration

NCT07269808

AnesthesiaSedation+1 more

View study

RECRUITINGNA

Artificial Intelligence Versus Conventional Digital Design for Fixed Dental Prosthesis

NCT07432165

Accuracy of Artificial Intelligence in Fixed Dental Prosthesis Design

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Artificial Intelligence in Assessing Gastric Intestinal Metaplasia Via the EGGIM Score

Inclusion Criteria

Exclusion Criteria

Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration

Artificial Intelligence Versus Conventional Digital Design for Fixed Dental Prosthesis

A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension

Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors

Endoscopy Immersion Study.

The GAstric Precancerous Conditions Study